研究の成果

バッド・キアリ症候群・Fontan術後肝合併症・うっ血肝

1. Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2021 Jun;15(3):531-567. https://pubmed.ncbi.nlm.nih.gov/34240318/
2. Fukushima M, Miyaaki H, Sasaki R, et al. Inferior vena cava anomalies with portal vein system continuation presenting as portal hypertension with a long-term follow-up. Intern Med. 2020 Nov 15;59(22):2897-2901. https://pubmed.ncbi.nlm.nih.gov/32713916/
3. Kawai H, Osawa Y, Mtasuda M, et al. Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy. Hepatology, 2021. doi: 10.1002/hep.32256. https://pubmed.ncbi.nlm.nih.gov/34855990/
4. Osawa, Y; Kawai, H, Tsunoda, T, et al. Cluster of differentiation 44 promotes liver fibrosis and serves as a biomarker in congestive hepatopathy. Hepatol. Comm. 2021 2021 Apr 8;5(8):1437-1447. https://pubmed.ncbi.nlm.nih.gov/34430787/
5. Komatsu H, Inui A, Kishiki K, et al. Liver disease secondary to congenital heart disease in children. Expert Rev Gastroenterol Hepatol. 2019;13(7):651-666. https://pubmed.ncbi.nlm.nih.gov/31131680/
6. Cho Y, Kabata D, Ehara E, et al. Assessing liver stiffness with conventional cut-off values overestimates liver fibrosis staging in patients who received the Fontan procedure. Hepatol Res. 2021 May;51(5):593-602. https://pubmed.ncbi.nlm.nih.gov/ 33677839/